Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
- PMID: 29183082
- DOI: 10.1001/jama.2017.16691
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Abstract
Importance: Hidradenitis suppurativa (HS) is relatively common, with the prevalence of 0.05% to 4.10%, yet many patients receive inadequate treatment.
Objective: To review the diagnosis, epidemiology, and treatment of HS with an emphasis on advances in the last 5 years.
Evidence review: A literature search was conducted using PubMed, MEDLINE (Medical Subject Headings [MeSH]), and EMBASE to include recently published treatment studies (searched from September 1, 2011, to May 1, 2017). Reviews, guidelines, conference abstracts, and studies with less than 10 patients were excluded. Furthermore, internet searches for guidelines on hidradenitis suppurativa using Baidu, Bing, Google, and Qwant browsers were performed.
Findings: The diagnosis of HS is made by lesion morphology (nodules, abscesses, tunnels, and scars), location (axillae, inframammary folds, groin, perigenital, or perineal), and lesion progression (2 recurrences within 6 months or chronic or persistent lesions for ≥3 months). HS is more common than was previously thought based on epidemiological analysis (0.05%-4.10%). Disability from HS can be significant. Patients with HS may have significant comorbidities (eg, obesity, metabolic syndrome, diabetes, and arthritis) and increased all-cause mortality (incidence rate ratio, 1.35 [95% CI, 1.15-1.59]). Antibiotic treatment with combinations of clindamycin and rifampicin, or ertapenem followed by combination rifampicin, moxifloxacin, and metronidazole for 6 months is effective. Adalimumab is effective in a significant proportion of patients and treatment with IL-1 and IL-12 receptor subunit beta 1 (Rb1) antibodies may also be useful. Tissue-sparing surgical techniques and carbon dioxide laser treatments also are available, but the evidence on clinical outcomes with these approaches is limited.
Conclusions and relevance: Hidradenitis suppurativa is more common than previously thought and may be treated by an array of pharmacological and surgical techniques. Hidradenitis suppurativa should be considered in the differential diagnosis of nodular lesions or sinus tracts present in the axillae, groin, perineal, and mammillary fold regions.
Comment in
-
Diagnosis and Treatment of Hidradenitis Suppurativa.JAMA. 2018 Apr 17;319(15):1617-1618. doi: 10.1001/jama.2018.0814. JAMA. 2018. PMID: 29677295 No abstract available.
-
Diagnosis and Treatment of Hidradenitis Suppurativa.JAMA. 2018 Apr 17;319(15):1618. doi: 10.1001/jama.2018.0818. JAMA. 2018. PMID: 29677296 No abstract available.
Similar articles
-
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110. Acta Dermatovenerol Croat. 2021. PMID: 34477078
-
Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.Curr Pharm Biotechnol. 2021;22(1):59-72. doi: 10.2174/1389201021666200505100556. Curr Pharm Biotechnol. 2021. PMID: 32368973 Review.
-
Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.Dermatol Online J. 2013 Apr 15;19(4):1. Dermatol Online J. 2013. PMID: 24021361 Review.
-
Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.Clin Exp Dermatol. 2021 Jan;46(1):96-102. doi: 10.1111/ced.14388. Epub 2020 Sep 17. Clin Exp Dermatol. 2021. PMID: 32683727
-
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.Rev Endocr Metab Disord. 2016 Sep;17(3):343-351. doi: 10.1007/s11154-016-9328-5. Rev Endocr Metab Disord. 2016. PMID: 26831295 Free PMC article. Review.
Cited by
-
An online longitudinal study about search index reflexing public attention of vaccinate against COVID-19.Ann Transl Med. 2022 Aug;10(15):827. doi: 10.21037/atm-22-3064. Ann Transl Med. 2022. PMID: 36035006 Free PMC article.
-
Hidradenitis suppurativa: a new therapeutic approach for an old disease.Postepy Dermatol Alergol. 2024 Aug;41(4):350-356. doi: 10.5114/ada.2024.142185. Epub 2024 Aug 12. Postepy Dermatol Alergol. 2024. PMID: 39290899 Free PMC article. Review.
-
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications.J Clin Med. 2022 Mar 10;11(6):1511. doi: 10.3390/jcm11061511. J Clin Med. 2022. PMID: 35329838 Free PMC article. Review.
-
Factors influencing inpatient hospitalization for hidradenitis suppurativa: a retrospective cohort study of 59,100 ED visits (2015-2019).Arch Dermatol Res. 2023 Dec;315(10):2999-3001. doi: 10.1007/s00403-023-02728-w. Epub 2023 Oct 5. Arch Dermatol Res. 2023. PMID: 37796340 No abstract available.
-
Racial Disparities in Hidradenitis Suppurativa Management at a Single Institution.Plast Reconstr Surg Glob Open. 2025 Jun 10;13(6):e6803. doi: 10.1097/GOX.0000000000006803. eCollection 2025 Jun. Plast Reconstr Surg Glob Open. 2025. PMID: 40496992 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous